🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we announced that Arcus obtained a term loan facility from Herucles Capital, adding operational flexibility and funding to advance our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer. Read more about this news bit.ly/3T2iyRK

Today we announced a clinical trial collaboration with AstraZeneca, representing part of Arcus’s development strategy to pursue a 1st-line differentiated combination of investigational molecule casdatifan for the treatment of #kidneycancer. Read more: bit.ly/3ZPTBwW

The first clinical data for casdatifan, our HIF-2a inhibitor for the treatment of #kidneycancer will be presented in an oral plenary session at #ENASymp24. Read more about this news and the posters we’ll be presenting: bit.ly/3YeEM5Y

The first clinical data for casdatifan were presented today in an oral plenary session at #ENASymp24. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat #kidneycancer. Read here: bit.ly/4hlvBZ4

As Arcus chase Merck's belzutifan in the HIF-2α space, can casdatifan live up to its preclinical promise and translate some nice features into robust lasting benefits? We take a look at the latest evidence: bit.ly/4dXqviz

The first overall survival results to be reported for the combination of domvanalimab and zimberelimab in #lungcancer will be presented in a late-breaking poster at Society for Immunotherapy of Cancer. Read about this news and other data we’ll be presenting: bit.ly/3Uw87X5 #SITC24

Today we announced the first overall survival results for the combination of investigational molecules domvanalimab and zimberelimab in #lungcancer. These data will be presented at #SITC24 this week. Read here: bit.ly/4hOauPl

We’re reporting our third-quarter financial results and an update on our clinical-stage pipeline. bit.ly/4fco90T

We are thrilled to welcome Richard Markus, M.D., Ph.D., to the Arcus team as chief medical officer. He will oversee our clinical development organization and its late-stage portfolio. bit.ly/40LlSDV

New clinical data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #kidneycancer will be presented in a rapid oral session this Saturday at the ASCO #GU25 Symposium. Read more about this news: bit.ly/4hNQ08n

New clinical data for casdatifan were presented today in a rapid oral session at ASCO #GU25. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat #kidneycancer. Read about the data: bit.ly/4gGo5Gr

Today we announced that Arcus will retain the rights to casdatifan, our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer, and shared pricing of $150 million common stock offering. Read the news here: bit.ly/3X2tL6E

We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline: bit.ly/41iuPEC

First combination data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #KidneyCancer, will be presented in an oral session at the #ASCO25 Annual Meeting. Read more about this news: bit.ly/42VUcya

We’re reporting our first-quarter financial results and an update on our clinical-stage pipeline. bit.ly/3SnOAqp

The first combination data for our HIF-2a inhibitor for the treatment of #KidneyCancer were presented today in an oral session at #ASCO25. Read more about the data and our rapidly advancing development program for casdatifan: bit.ly/4juXYUj

We are thrilled to announce the U.S. FDA has granted Orphan Drug Designation to our investigational small molecule CD73 inhibitor quemliclustat, for the treatment of #PancreaticCancer, a rare disease which has seen few treatment advancements over the past 30 years. Learn more: